Avid Bioservices Inc (CDMO)

[Krakonos]

Seagull2, they already announced it (indirectly):


Bavituximab is our lead immunotherapy candidate entering Phase III development for the treatment of NSCLC.
(Top of page 2)

It doesn't say "it will enter".
In my mind entering is something happening presently.